미국 - 영어 - NLM (National Library of Medicine)

medical purchasin solutions, llc - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. vasostrict ® is contraindicated in patients with known allergy or hypersensitivity to 8-l-arginine vasopressin or chlorobutanol. pregnancy category c risk summary: there are no adequate or well-controlled studies of vasostrict ® in pregnant women. it is not known whether vasopressin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. animal reproduction studies have not been conducted with vasopressin [see clinical pharmacology (12.3)]. clinical considerations: because of increased clearance of vasopressin in the second and third trimester, the dose of vasostrict ® may need to be up-titrated to doses exceeding 0.1 units/minute in post-cardiotomy shock and 0.07 units/minute in septic

미국 - 영어 - NLM (National Library of Medicine)

par pharmaceutical, inc. - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasostrict® 10 ml multiple dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑l-arginine vasopressin or chlorobutanol. the 1 ml single dose vial, 50 ml and 100 ml pre-mixed single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. risk summary there are no available data on vasostrict® use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.  animal reproduction studies have not been conducted with vasopressin. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasostrict® may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)] . maternal adverse reactions: vasostrict® may produce tonic uterine contractions that could threaten the continuation of pregnancy. there are no data on the presence of vasopressin injection in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. safety and effectiveness of vasostrict® in pediatric patients with vasodilatory shock have not been established. clinical studies of vasopressin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see warnings and precautions (5), adverse reactions (6), and clinical pharmacology (12.3)] .

미국 - 영어 - NLM (National Library of Medicine)

medical purchasing solutions, llc - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasostrict ® 10 ml multiple dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑l-arginine vasopressin or chlorobutanol.  the 1 ml single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. risk summary there are no available data on vasostrict ® use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasostrict® may need to be increased [see dosage and

미국 - 영어 - NLM (National Library of Medicine)

par pharmaceutical, inc. - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasostrict® 10 ml multiple dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑l-arginine vasopressin or chlorobutanol.  the 1 ml single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. risk summary there are no available data on vasostrict® use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.  animal reproduction studies have not been conducted with vasopressin. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasostrict® may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)] .

미국 - 영어 - NLM (National Library of Medicine)

sanpharma gmbh - sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20), anhydrous dibasic calcium phosphate (unii: l11k75p92j) (anhydrous dibasic calcium phosphate - unii:l11k75p92j, calcium cation - unii:2m83c4r6zb), calcium citrate (unii: mlm29u2x85) (calcium cation - unii:2m83c4r6zb), potassium bicarbonate (unii: hm5z15lebn) (potassium cation - unii:295o53k152), magnesium citrate (unii: rho26o1t9v) (magnesium cation - unii:t6v3lhy838) - sodium bicarbonate 60 g in 100 g - stir 1 level teaspoon into 1 glass of water and drink ½ hour before eating. nutrition experts recommend using it for 2 to 3 months as the body needs this time to neutralize and excrete excess acid. the recommended daily dose should not be exceeded.

미국 - 영어 - NLM (National Library of Medicine)

sanpharma gmbh - sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37), calcium citrate (unii: mlm29u2x85) (calcium cation - unii:2m83c4r6zb), dibasic calcium phosphate dihydrate (unii: o7tsz97gep) (anhydrous dibasic calcium phosphate - unii:l11k75p92j), potassium bicarbonate (unii: hm5z15lebn) (potassium cation - unii:295o53k152), magnesium citrate (unii: rho26o1t9v) (magnesium cation - unii:t6v3lhy838) - take 2 capsules 1-3 times a day with plenty of water ½ hour before eating. nutrition experts recommend using it for 2 to 3 months as the body needs this time to neutralize and excrete excess acid. the recommended daily dose should not be exceeded.

남아프리카 - 영어 - South African Health Products Regulatory Authority (SAHPRA)

unicorn pharmaceuticals (pty) ltd - tablet - see ingredients - each tablet contains valsartan 40,0 mg

남아프리카 - 영어 - South African Health Products Regulatory Authority (SAHPRA)

unicorn pharmaceuticals (pty) ltd - tablet - see ingredients - each tablet contains valsartan 80,0 mg

남아프리카 - 영어 - South African Health Products Regulatory Authority (SAHPRA)

unicorn pharmaceuticals (pty) ltd - tablet - see ingredients - each tablet contains valsartan 160,0 mg